Halozyme Therapeutics Inc. (HALO)

17.10
0.08 0.47
NASDAQ : Health Technology
Prev Close 17.18
Open 17.30
Day Low/High 16.95 / 17.47
52 Wk Low/High 11.41 / 21.48
Volume 669.98K
Avg Volume 742.60K
Exchange NASDAQ
Shares Outstanding 144.30M
Market Cap 2.52B
EPS 0.50
P/E Ratio 29.56
Div & Yield N.A. (N.A)

Latest News

Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology

Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology

SAN DIEGO, July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has dosed the first patient in...

First Week Of March 2019 Options Trading For Halozyme Therapeutics (HALO)

First Week Of March 2019 Options Trading For Halozyme Therapeutics (HALO)

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the March 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin

FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin

SAN DIEGO, July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.

Halozyme To Host Second Quarter 2018 Financial Results Conference Call

Halozyme To Host Second Quarter 2018 Financial Results Conference Call

SAN DIEGO, July 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2018 on Tues.

Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego

Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego

SAN DIEGO, June 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced Dr.

Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer

Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer

-- Janssen Presenting Five Clinical Studies of subcutaneous daratumumab with Halozyme ENHANZE Technology--

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATAX, COR, GPRK, KWR, NYLD Downgrades: CKH, CUTR, CYD, DRQ, EDAP, FLXS, GOLD, HALO, HDB, IRDM, KND, MSCC, XRX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,401,809 share decrease in total short interest for Halozyme Therapeutics Inc , to 10,232,867, a decrease of 12.05% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Halozyme Therapeutics Reaches Analyst Target Price

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $20.11, changing hands for $20.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Roku, Sierra Wireless, Visa, Cimarex Energy, First Solar, Halozyme Therapeutics.

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Don't buy big here and don't buy all at once, but it's not too late to ride this bull to profits, says Jim Cramer.

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc.

Exxon, Chevron, Cimarex Energy: 'Mad Money' Lightning Round

Exxon, Chevron, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exxon, Chevron, Cimarex Energy, Skechers USA, and Halozyme Therapeutics.

Trump Doesn't Get All the Credit: Cramer's 'Mad Money' Recap (Wed 11/8/17)

Trump Doesn't Get All the Credit: Cramer's 'Mad Money' Recap (Wed 11/8/17)

Jim Cramer says President Trump has been a great salesman, but when we look at winning stocks, it's the strong CEOs who are driving success.

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Proposals are having an effect ahead of afternoon announcement.

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

Good Stocks Are There for the Picking

Good Stocks Are There for the Picking

Focus on what could go right.

TheStreet Quant Rating: C (Hold)